Mark Zimmerman1, Iwona Chelminski, Michael A Posternak. 1. Department of Psychiatry and Human Behavior, Brown Medical School, Rhode Island Hospital, Providence, RI 02905, USA. mzimmerman@lifespan.org
Abstract
OBJECTIVE: In recent years the generalizability of antidepressant efficacy trials has been questioned. Central to the question of generalizability is whether there are differences in clinical, demographic, and psychosocial characteristics between patients who would qualify for an antidepressant efficacy trial and those who would not qualify. METHOD: The authors compared three groups: 123 depressed patients who would qualify for an antidepressant efficacy trial, 289 whose symptom severity was too mild to qualify for an antidepressant efficacy trial, and 187 who would be excluded because they were suicidal or had a comorbid anxiety or substance use disorder. RESULTS: Compared with patients who would qualify for an antidepressant efficacy trial, patients who would be excluded because of comorbidity or suicidality were a more chronically ill group with more previous episodes, greater psychosocial impairment, and more personality pathology. CONCLUSIONS: These findings support further caution in generalizing the results from antidepressant efficacy trials to clinical populations.
OBJECTIVE: In recent years the generalizability of antidepressant efficacy trials has been questioned. Central to the question of generalizability is whether there are differences in clinical, demographic, and psychosocial characteristics between patients who would qualify for an antidepressant efficacy trial and those who would not qualify. METHOD: The authors compared three groups: 123 depressedpatients who would qualify for an antidepressant efficacy trial, 289 whose symptom severity was too mild to qualify for an antidepressant efficacy trial, and 187 who would be excluded because they were suicidal or had a comorbid anxiety or substance use disorder. RESULTS: Compared with patients who would qualify for an antidepressant efficacy trial, patients who would be excluded because of comorbidity or suicidality were a more chronically ill group with more previous episodes, greater psychosocial impairment, and more personality pathology. CONCLUSIONS: These findings support further caution in generalizing the results from antidepressant efficacy trials to clinical populations.
Authors: Gregory J McHugo; Robert E Drake; Mary F Brunette; Haiyi Xie; Susan M Essock; Alan I Green Journal: Schizophr Bull Date: 2006-07-18 Impact factor: 9.306
Authors: Jeanette W Chung; Karl Y Bilimoria; Jonah J Stulberg; Christopher M Quinn; Larry V Hedges Journal: Health Serv Res Date: 2017-08-21 Impact factor: 3.402
Authors: Ira M Lesser; Hector F Myers; Keh-Ming Lin; Consuelo Bingham Mira; Nataria T Joseph; Natasha T Olmos; Jonathan Schettino; Russell E Poland Journal: Depress Anxiety Date: 2010 Impact factor: 6.505
Authors: Koen Demyttenaere; Anne Verhaeghen; Nicolas Dantchev; Luigi Grassi; Angel L Montejo; David G S Perahia; Deborah Quail; Catherine Reed; Andre Tylee; Michael Bauer Journal: Prim Care Companion J Clin Psychiatry Date: 2009